Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant
Susan DeWolf, Steven J. Siegel, Joseph Schmalz, Wael Saber, Alexandre Albanese, Jiayi Dong, Michael J. Martens, Brent R. Logan, Lorenzo Iovino, Kayleigh Ingersoll Omdahl, Nicholas Winn, Edward Chen, James J. Kaminski, Donna S Neuberg, Kyle M. Hebert, Paula Keskula, Jillian Zavistaski, Lea Steinberg, Isabella Schichter, Zoe Katsamakis, Lorenzo S Cagnin, Vanessa A Hernandez, Makya Warren, Kristy Applegate, Merav Bar, Saurabh Chhabra, Sung Won Choi, William Clark, Suman R. Das, Robert R. Jenq, Richard John Jones, John E. Levine, Hemant S. Murthy, Armin Rashidi, Marcie Riches, Karamjeet Sandhu, Anthony Derek Sung, Karilyn T. M. Larkin, Monzr M. Al Malki, Mahasweta Gooptu, Hany Elmariah, Amin Majid Alousi, Lyndsey Runaas, Brian C. Shaffer, Andrew R. Rezvani, Najla El Jurdi, Alison Wakoff Loren, Danielle Scheffey, Catherine Miller Sanders, Mehdi Hamadani y 9 más
Revista con revisión por paresUso en el mundo real
En palabras de los autores
Esta revista no permite republicar el resumen completo. Estas son las dos oraciones que eligió Pipette, citadas textualmente. El resto está en el sitio de la editorial.
Resultado principal
This study reveals how distinct immunosuppression strategies uniquely remodel T cell immunity and shape divergent transplant outcomes.
In conclusion, dabrafenib is a low–molecular weight compound that inhibits cavernoma pathogenesis, suggesting that CCMs could be treated with dabrafenib to block cavernoma growth and vascular leakage.
Maximiliano Arce, Hua Huang, Charlotte Rorsman y 13 más — Science Translational Medicine
Revista con revisión por paresUso en el mundo real
Our results show that even the structurally minimal class A GPCRs are viable targets for de novo cyclic peptide discovery, highlighting the potential for uncovering ligands towards other members of the GPCR superfamily.
F. Salgado-Polo, M. Matic, P. B. Rainsford y 9 más — bioRxiv
Employing this assay, structure-based drug design by protein X-ray crystallography, structure-activity relationship (SAR) analyses, and in vitro and in vivo validation, we developed novel CYP8B1-specific small molecule inhibitors.
Z. Fang, A. R. L. Agua, J. Jossart y 17 más — bioRxiv
PreprintAfirmaciones fuertes, leer con cuidadoDice ser un gran avanceUso en el mundo real
We developed a humanized anti-ZIP12 monoclonal antibody, APL-9796, that normalized intracellular Zn 2+ concentration, suppressed proliferation in fibroblasts derived from patients with PAH and PDGF-stimulated PASMCs, and reduced PDGF-induced cytoskeletal remodeling in PASMCs and contractility in PASMCs and engineered pulmonary artery tissues.
Lan Zhao, Lan Zhao, Stephanie Hopley y 18 más — Science Translational Medicine
Revista con revisión por paresAfirmaciones fuertes, leer con cuidadoUso en el mundo real